MSD Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions
Today marks the midway milestone for World Rabies Day, when the Global Alliance for Rabies Control, together with health organizations from around the world, set a goal of eliminating human rabies transmitted by dogs by 2030. MSD Animal Health (known as Merck Animal Health in the United States and Canada) is pleased to announce our continued support in the fight against rabies through the donation of NOBIVAC® Rabies vaccine and other resources to the Afya Serengeti Project and Mission Rabies, organizations working to eliminate this disease in the world’s most at-risk regions.
Rabies, a neglected disease of vulnerable populations, is nearly 100 percent fatal but also nearly 100 percent preventable through canine vaccination. Yet midway to the global health community’s deadline for eliminating canine-mediated rabies, Africa and India still bear the highest burden of total annual rabies deaths.i Countries with the highest fatalities from rabies are India, Democratic Republic of the Congo, Ethiopia, China and Myanmar.ii
“Each year, an estimated 60,000 people die from rabies, with 40 percent of those deaths occurring in children under the age of fifteen,” said Ingrid Deuzeman, global marketing director, MSD Animal Health. “We are resolved to continue our collaboration with the Afya Serengeti Project, which we’ve been committed to for more than 15 years, and with Mission Rabies, in support of the global health community goal to eliminate rabies.”
Progress in the Fight Against Rabies
In more than 20 participating countries, when pet owners and veterinarians choose NOBIVAC vaccines, it allows MSD Animal Health to donate rabies vaccine to Mission Rabies and the Afya Serengeti Project.
“Mission Rabies launched at the end of 2013 and to date we’ve delivered the NOBIVAC Rabies vaccine to 700,000 street dogs in some of the world’s worst rabies hotspots. Our flagship projects are delivering amazing results with no human rabies cases having been reported in the Indian city of Ranchi, the State of Goa or the city of Blantyre in Malawi so far this year. It’s incredible considering just a few years ago, a hospital in Blantyre (the Queen Elizabeth Central Hospital) was reporting the highest incidence of child rabies deaths from any single institution in the whole of Africa,” said Luke Gamble, founder, Mission Rabies. “We are all driven to power Mission Rabies forward and without the support of MSD Animal Health NOBIVAC Rabies vaccine, we couldn’t do what we do. The vaccine is saving lives amongst some of the poorest and most vulnerable people in the world and it’s a privilege to be a part of this project with everyone.”
“The human toll of rabies is needless and tragic. However, over the past 20 years, we have shown that vaccination programs can reach enough dogs to eliminate rabies anywhere in the world,” said Professor Sarah Cleaveland, founder, Afya Serengeti Project. “With continued support from MSD Animal Health and other collaborators, I believe we have the vaccine and the tools to achieve zero human deaths from dog rabies by 2030.”
Eliminating Rabies in India and Africa
Since 2013, Mission Rabies has set a goal to vaccinate dogs across rabies hotspots in India, where over a third of all human rabies deaths occur.iii Based on the program’s success in India, Mission Rabies has expanded its offering to Africa.
Mission Rabies does more than just vaccinate hundreds of thousands of dogs against rabies each year. They go to schools and educate children in these communities, informing them of the seriousness of the disease. Children are the most affected by rabies because they play with dogs and don’t understand how deadly rabies can be.
Using a fast-paced team of veterinarians and volunteers, Mission Rabies has so far vaccinated more than 505,000 dogs, trained 80 veterinarians, and educated more than 1,200,000 children about the risk of rabies.
Saving Lives in the Serengeti
The Afya Serengeti Project has prevented thousands of deaths in the Serengeti through the widespread vaccination of domestic dogs. Since the start of the program, the incidence of human rabies, rabies in dogs and rabid dog bites has dropped to an all-time low.iv Each year, over 600 dog rabies cases have been prevented and 23 human lives saved. The effective control of rabies through dog vaccination has also had benefits for wildlife, including endangered African wild dogs, which have become re-established in the Serengeti National Park for the first time since the population disappeared as a result of rabies outbreaks in the early 1990s. Understanding the importance of providing vaccinations to other at-risk areas, the Afya Project has extended to Kenya, Bangalore and the Pune region of India.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
i World Health Organization. Rabies Fact Sheet: Epidemiology.
Accessed June 23, 2017 at http://www.who.int/rabies/epidemiology/en/.
ii Hampson K, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4). Accessed June 23, 2017 at http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003709#pntd.0003709.s002.
iii World Health Organization. Bulletin of the World Health Organization. “India’s ongoing war against rabies.” Bulletin of the World Health Organization. Volume 87, Number 12, December 2009, 885-964. Accessed June 17, 2015 via http://www.who.int/bulletin/volumes/87/12/09-021209/en/.
iv Kaare M, Lembo T, Hampson K, et al. Rabies control in rural Africa: evaluating strategies for effective domestic dog vaccination. Vaccine. 2009;27(1):152–160.
MSD Animal Health
Logan Rizzo, +1-973-937-5590
Pam Eisele, +1-267-305-3558
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201721.10.2017 00:00 | Tiedote
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 18:08 | Tiedote
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 15:15 | Tiedote
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 15:03 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 14:00 | Tiedote
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 13:47 | Tiedote
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme